In the light of our results, ADAM10 inhibition may present a complementary strategy to block the ADAM10 –E-cadherin–EGFR family member axis and thereby not only execute anti-HCV activity but also reduce the risk of cancer development in chronic HCV patients. This evidence concerns the gene ADAM10 and cancer.